Exact Sciences Corporation

45.15+2.91+6.89%Vol 3.20M1Y Perf -67.13%
Jun 24th, 2022 16:00 DELAYED
BID44.36 ASK45.13
Open42.51 Previous Close42.24
Pre-Market- After-Market44.87
 - -  -0.28 -0.62%
Target Price
98.40 
Analyst Rating
Strong Buy 1.25
Potential %
117.94 
Finscreener Ranking
★★★+     50.92
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★     46.08
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★+     47.57
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
9.94 
Earnings Rating
Buy
Market Cap7.94B 
Earnings Date
27th Jul 2022
Alpha0.00 Standard Deviation0.15
Beta1.24 

Today's Price Range

42.0945.18

52W Range

35.34133.99

5 Year PE Ratio Range

-54.20-28.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
21.96%
1 Month
-6.77%
3 Months
-32.28%
6 Months
-42.20%
1 Year
-67.13%
3 Years
-59.49%
5 Years
27.15%
10 Years
341.78%

TickerPriceChg.Chg.%
EXAS45.152.91006.89
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
2.10
2.50
0.42
0.73
-58.00
Leverage Ratio 1.90
ProfitabilityValueIndustryS&P 500US Markets
73.90
-39.90
-29.90
-46.60
-40.11
RevenueValueIndustryS&P 500US Markets
1.85B
10.52
44.08
64.93
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.12-1.047.14
Q04 2021-0.91-1.28-40.66
Q03 2021-0.89-0.97-8.99
Q02 2021-0.72-1.03-43.06
Q01 2021-1.04-0.1882.69
Q04 2020-0.19-0.0952.63
Q03 2020-0.51-0.3629.41
Q02 2020-0.62-0.586.45
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.090.00-
9/2022 QR-1.10-3.77Negative
12/2022 FY-4.281.15Positive
12/2023 FY-3.27-0.93Negative
Next Report Date27th Jul 2022
Estimated EPS Next Report-1.08
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume3.20M
Shares Outstanding175.95K
Shares Float155.72M
Trades Count41.30K
Dollar Volume141.35M
Avg. Volume2.24M
Avg. Weekly Volume2.45M
Avg. Monthly Volume2.14M
Avg. Quarterly Volume2.12M

Exact Sciences Corporation (NASDAQ: EXAS) stock closed at 45.15 per share at the end of the most recent trading day (a 6.89% change compared to the prior day closing price) with a volume of 3.20M shares and market capitalization of 7.94B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 5000 people. Exact Sciences Corporation CEO is Kevin T. Conroy.

The one-year performance of Exact Sciences Corporation stock is -67.13%, while year-to-date (YTD) performance is -41.99%. EXAS stock has a five-year performance of 27.15%. Its 52-week range is between 35.34 and 133.99, which gives EXAS stock a 52-week price range ratio of 9.94%

Exact Sciences Corporation currently has a PE ratio of -9.50, a price-to-book (PB) ratio of 2.23, a price-to-sale (PS) ratio of 3.54, a price to cashflow ratio of 364.30, a PEG ratio of 2.32, a ROA of -11.60%, a ROC of -12.57% and a ROE of -22.24%. The company’s profit margin is -40.11%, its EBITDA margin is -29.90%, and its revenue ttm is $1.85 Billion , which makes it $10.52 revenue per share.

Of the last four earnings reports from Exact Sciences Corporation, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.08 for the next earnings report. Exact Sciences Corporation’s next earnings report date is 27th Jul 2022.

The consensus rating of Wall Street analysts for Exact Sciences Corporation is Strong Buy (1.25), with a target price of $98.4, which is +117.94% compared to the current price. The earnings rating for Exact Sciences Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Exact Sciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Exact Sciences Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.90, ATR14 : 3.43, CCI20 : 0.51, Chaikin Money Flow : -0.08, MACD : -3.44, Money Flow Index : 51.25, ROC : -6.13, RSI : 49.57, STOCH (14,3) : 62.17, STOCH RSI : 1.00, UO : 55.19, Williams %R : -37.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Exact Sciences Corporation in the last 12-months were: James E. Doyle (Option Excercise at a value of $214 760), James E. Doyle (Sold 2 640 shares of value $293 489 ), Jeffrey T. Elliott (Option Excercise at a value of $311 127), Jeffrey T. Elliott (Sold 45 807 shares of value $4 837 927 ), Katherine S. Zanotti (Sold 1 381 shares of value $153 439 ), Kevin T. Conroy (Option Excercise at a value of $5 851 572), Kevin T. Conroy (Sold 114 628 shares of value $10 878 114 ), Sarah Condella (Option Excercise at a value of $318 020), Sarah Condella (Sold 20 716 shares of value $1 549 462 ), Scott D. Coward (Option Excercise at a value of $622 254), Scott D. Coward (Sold 9 756 shares of value $741 613 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (83.33 %)
10 (83.33 %)
10 (83.33 %)
Moderate Buy
1 (8.33 %)
1 (8.33 %)
1 (8.33 %)
Hold
1 (8.33 %)
1 (8.33 %)
1 (8.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.25
Strong Buy
1.25

Exact Sciences Corporation

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.

CEO: Kevin T. Conroy

Telephone: +1 608 284-5700

Address: 441 Charmany Drive, Madison 53719, WI, US

Number of employees: 5 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

62%38%

Bearish Bullish

59%41%

TipRanks News for EXAS

Thu, 28 Apr 2022 04:25 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Exact Sciences (EXAS), Teladoc (TDOC) and Guardant Health (GH)

- TipRanks. All rights reserved.

Thu, 28 Apr 2022 02:06 GMT Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Exact Sciences (EXAS) and Cochlear Limited (OtherCHEOF)

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 12:36 GMT Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Exact Sciences (EXAS) and Mednax (MD)

- TipRanks. All rights reserved.

Tue, 25 Jan 2022 20:26 GMT Exact Sciences: Could Decline More in 2022

- TipRanks. All rights reserved.

Thu, 20 Jan 2022 13:25 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Encompass Health (EHC)

- TipRanks. All rights reserved.

Thu, 20 Jan 2022 08:45 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS) and MannKind (MNKD)

- TipRanks. All rights reserved.

Thu, 20 Jan 2022 01:25 GMT Analysts Top Healthcare Picks: Exact Sciences (EXAS), UnitedHealth (UNH)

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 18:20 GMT Exact Sciences (EXAS) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 18:15 GMT Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and NanoString Tech (NSTG)

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 15:26 GMT Analysts Top Healthcare Picks: Exact Sciences (EXAS), BioAtla (BCAB)

- TipRanks. All rights reserved.

News

Stocktwits